Leadership Overview
Novavax has 4 executives leading key functions including human resources, medical affairs, legal, and clinical development.
Driven by a commitment to global health, Novavax focuses on discovering, developing, and commercializing vaccines to combat serious infectious diseases, leveraging a proprietary technology platform to enhance immune response and address unmet medical needs worldwide.
Driven by a commitment to global health, Novavax focuses on discovering, developing, and commercializing vaccines to combat serious infectious diseases, leveraging a proprietary technology platform to enhance immune response and address unmet medical needs worldwide.
Leadership Roles at Novavax
Ian Watkins - Executive Vice President & Chief Human Resources Officer
Ian Watkins, the Executive Vice President & Chief Human Resources Officer at Novavax, directs all global human capital strategies. Overseeing talent acquisition, development, and retention, Watkins ensures Novavax cultivates a high-performing workforce essential for vaccine innovation. This leadership role involves fostering a culture that supports scientific advancement and operational excellence across the organization. By aligning HR initiatives with the company's mission to protect against serious infectious diseases, Ian Watkins drives employee engagement and organizational effectiveness. The focus remains on building a robust team capable of navigating the complexities of biotechnology and global health challenges. Watkins's strategic oversight ensures that Novavax's most valuable asset – its people – are empowered to achieve the company's ambitious goals in vaccine development and commercialization.
Louis Fries - Chief Medical Officer
Louis Fries, the Chief Medical Officer at Novavax, spearheads the company's clinical strategy and medical affairs. Directing the execution of clinical trials, Fries ensures the rigorous evaluation of Novavax's vaccine candidates against serious infectious diseases. This critical role involves translating scientific discoveries into tangible health solutions, guiding the development pipeline from early-stage research through regulatory submission. By overseeing medical operations, Louis Fries ensures adherence to the highest ethical and scientific standards, crucial for building trust and demonstrating the efficacy of Novavax's proprietary technology platform. The Chief Medical Officer's leadership is central to advancing vaccine candidates targeting diseases like COVID-19 and influenza, directly impacting Novavax's ability to deliver on its mission. Fries's expertise guides the company's approach to clinical development, ensuring that Novavax's innovations reach populations in need worldwide.
Mark Casey - Executive Vice President & Chief Legal Officer
Mark Casey, the Executive Vice President & Chief Legal Officer at Novavax, provides strategic legal counsel and oversees all corporate governance. Directing the legal department, Casey manages intellectual property, regulatory compliance, and complex contractual agreements, safeguarding Novavax's innovative vaccine development and commercialization efforts. This leadership position is vital for navigating the intricate global regulatory landscape and protecting the company's proprietary technology platform. By ensuring robust legal frameworks, Mark Casey supports Novavax's mission to protect against serious infectious diseases. The Chief Legal Officer's purview extends to managing litigation, advising on mergers and acquisitions, and ensuring adherence to securities laws, thereby fortifying Novavax's market position. Casey's guidance is instrumental in enabling Novavax to pursue its scientific objectives with confidence and integrity.
Raburn Mallory - Senior Vice President, Head of Clinical Development and Deputy Chief Medical Officer
Raburn Mallory, the Senior Vice President, Head of Clinical Development and Deputy Chief Medical Officer at Novavax, supports the Chief Medical Officer in advancing the company's vaccine pipeline. Directing key aspects of clinical trial design and execution, Mallory ensures the efficient and effective evaluation of Novavax's vaccine candidates targeting serious infectious diseases. This role is critical for translating the company's proprietary technology platform into viable public health solutions. By overseeing the operational details of clinical development, Raburn Mallory contributes significantly to Novavax's ability to bring innovative vaccines to market. The focus remains on rigorous scientific methodology and timely data generation to support regulatory submissions. Mallory's leadership in clinical development is essential for Novavax's ongoing efforts to combat global health threats and fulfill its mission.
Explore Leadership Teams in Blood & Organ Banks
OneBlood, headquartered in Orlando, Florida, is a non-profit organization that specializes in blood donation for hospitals.
Company Leadership GS
CN
VC
SP
Carter BloodCare is an independent, community blood center providing transfusion resources. Services include collection, processing, specialized laboratory testing, storage and distribution of blood and blood products. The program is accredited by the AABB, including a laboratory with accreditation for molecular testing of red cell antigens. It is licensed by the U.S. Food and Drug Administration and is a member of America's Blood Centers.
Company Leadership SP
VM
NJ
BG
Established in 1975, the Gulf Coast Regional Blood Center is headquartered in Houston, Texas. They serve more than 170 hospitals and healthcare institutions in the Texas Gulf Coast, Brazos Valley, and East Texas regions.
Company Leadership
BG
SR
DM
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Company Leadership MP
HA
KL
SL
Frequently Asked Questions Regarding Novavax Top Executives and Leadership Team
